小分子酪氨酸激酶抑制剂治疗非小细胞肺癌的回顾性分析

Retrospective Analysis of Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Non-small Cell Lung Cancer

目的:评价小分子酪氨酸激酶抑制剂用于治疗非小细胞肺癌(NSCLC)的疗效及安全性。方法:回顾性收集2012-2014年新疆石河子大学医学院第一附属医院和新疆克拉玛依市中心医院收治的NSCLC患者24例,均接受厄洛替尼150 mg,qd,或吉非替尼250 mg,qd治疗,直至病情进展或患者无法耐受不良反应停药。采用世界卫生组织(WHO)实体瘤近期疗效评价标准进行疗效评价,观察生存率,对不同因素类型进行单因素分析,并记录患者不良反应发生率。结果:不同病理类型之间,腺癌患者较非腺癌患者中位无进展生存期(PFS)和中位总生存期(OS)延长,差异有统计学意义(P<0.05)。患者主要不良反应为皮疹(45.8%)、腹泻(16.7%)。结论:小分子酪氨酸激酶抑制剂治疗非小细胞肺癌的临床效果较好,且腺癌患者中位PFS和中位OS较高,不良反应较轻。

OBJECTIVE：To evaluate therapeutic efficacy and safety of small molecule tyrosine kinase inhibitors in the treatment of non-small cell lung cancer（NSCLC）.METHODS：In retrospective study,24 NSCLC patients were collected from the First Affiliated Hospital of Xinjiang Shihezhi University School of Medicine and Karamay Center Hospital during 2012-2014.They were given erlotinib 150 mg,qd,or gefitinib 250 mg,qd,till disease changed or patients could not tolerate ADR.Therapeutic efficacy was evaluated by using WHO solid tumor short-term efficacy evaluation criteria;survival rate was observed and single factor analysis was conducted for different factor types,and the incidence of ADR was recorded.RESULTS：Among different pathological types,progression-free survival（PFS）of adenocarcinoma patients prolonged,compared to non-adenocarcinoma patients,with statistical significance（P〈0.05）.The main ADR were skin rash（45.8%）and diarrhea（16.7%）.CONCLUSIONS：Small molecule tyrosine kinase inhibitors is effective for NSCLC;median PFS and median OS of adenocarcinoma patients is significantly higher than other pathological types,and ADR is slighter.